Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRILOGY long‑term extension study of guselkumab in pediatric Crohn's disease, ulcerative colitis, and juvenile psoriatic arthritis
jRCT2071250012Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of guselkumab in Crohn's disease, autoimmune colitis and juvenile psoriatic arthritis (JPsA) (2 arms), sponsored by Janssen Pharmaceutical. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseautoimmune colitisjuvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on jRCT2071250012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250012.